As the official podcast of the American College of Rheumatology (ACR), ACR on Air seeks to have
informative and engaging conversations rheumatology professionals want to hear – ranging in topic from trends in
clinical practice, to issues affecting rheumatology professionals, and the changing landscape of the rheumatology
field. Tune in each month for engaging interviews and commentary.
Sneak Peek of “Hot Off the Press at ACR Convergence”
ACR Convergence 2022 is almost here, and with that, new trials, new medications and new results. We’re preparing a very HOT episode for you, to be released along with the opening ceremony at ACR Convergence 2022, this Saturday, November 12th. In this preview of Saturday’s full episode, we’ve invited host of “ACR Journals on Air” Dr. Vicki Shanmugam, to briefly discuss all the exciting science that is just a few days away!
11/8/2022 • 5 minutes, 49 seconds
38. Revisiting the Great Debate JAKs vs TNFs
During “The Great Debate” at ACR Convergence 2020, the question: “Should JAK inhibitors be started before TNF inhibitors in people with rheumatoid arthritis who failed methotrexate?” was asked. However, in 2021, results from the oral surveillance trial showed an increased risk of major adverse cardiovascular events in cancers among patients with rheumatoid arthritis taking tofacitinib as compared to those on TNF inhibitors. These findings led to the FDA updating their black box warning on JAK inhibitors. Today, we’ve invited one of the speakers on the great debate, Dr. Vibeke Strand, to speak on her position on JAK inhibitors given these new results and shed some more light on the subject.
